Stent Parameters Predict Major Adverse Clinical Events and the Response to Platelet Glycoprotein IIb/IIIa Blockade: Findings of the ESPRIT Trial

Circulation: Cardiovascular Interventions - United States
doi 10.1161/circinterventions.108.809285
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Platelet Inhibition With an Antibody to Glycoprotein IIb/IIIa

Circulation
Cardiovascular MedicinePhysiologyCardiology
1989English

Platelet Inhibition After Glycoprotein IIb/IIIa Inhibitor Therapy

Circulation
Cardiovascular MedicinePhysiologyCardiology
2001English

Deaths Associated With Platelet Glycoprotein IIb/IIIa Inhibitor Treatment

Heart
2003English

Platelet Glycoprotein IIb/IIIa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery Disease

Circulation
Cardiovascular MedicinePhysiologyCardiology
2003English

Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes

JAMA - Journal of the American Medical Association
Medicine
2000English

Role of Platelet Membrane Glycoprotein IIb-IIIa in Agonist-Induced Tyrosine Phosphorylation of Platelet Proteins

Journal of Cell Biology
MedicineCell Biology
1990English

Comparative Antithrombotic Effects of Magnesium Sulfate and the Platelet Glycoprotein IIb/IIIa Inhibitors Tirofiban and Eptifibatide in a Canine Model of Stent Thrombosis

Circulation
Cardiovascular MedicinePhysiologyCardiology
2002English

Glycoprotein IIb/IIIa Induced Coronary Thrombolysis

Heart
2002English

Effects of Monoclonal Antibodies Against the Platelet Glycoprotein IIb/IIIa Complex on Thrombosis and Hemostasis in the Baboon.

Journal of Clinical Investigation
Medicine
1988English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy